Neuropace Inc

NPCE

13.330USD

-0.330-2.42%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Neuropace Inc's Score

Industry at a Glance

Industry Ranking

48 / 208

Overall Ranking

145 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Neuropace Inc Highlights

StrengthsRisks

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.83% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 99.99M.

Undervalued

The company’s latest PE is -20.32, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.63M shares, decreasing 17.30% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

19.875

Target Price

+45.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Neuropace Inc is 6.61, ranking 136 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 26.59M, representing a year-over-year increase of 23.86%, while its net profit experienced a year-over-year increase of 48.02%.

Score

Industry at a Glance

Previous score

6.61

Change

0



Financials

5.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.94

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.94

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.12

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Neuropace Inc is 7.15, ranking 119 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -20.32, which is -96.30% below the recent high of -0.75 and -13.85% above the recent low of -23.14.

Score

Industry at a Glance

Previous score

7.15

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Neuropace Inc is 8.50, ranking 24 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 18.00, with a high of 20.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Neuropace Inc is 7.17, ranking 30 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 15.18 and the support level at 12.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.37

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Neuropace Inc is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 92.59%, representing a quarter-over-quarter decrease of 1.64%. The largest institutional shareholder is The Vanguard, holding a total of 1.48M shares, representing 4.40% of shares outstanding, with 20.53% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Accelmed Growth Partners Management Ltd

4.43M

--

Polar Capital LLP

3.10M

--

Soleus Capital Management, L.P.

2.96M

+27.89%

Morgan Stanley & Co. LLC

2.54M

-1.51%

OrbiMed Advisors, LLC

2.61M

--

BlackRock Institutional Trust Company, N.A.

1.64M

+6.76%

Driehaus Capital Management, LLC

939.52K

-6.55%

The Vanguard Group, Inc.

Star Investors

1.44M

+4.86%

First Light Asset Management, LLC

1.36M

-1.47%

Kent Lake PR LLC

1.00M

+8.11%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuropace Inc is 3.82, ranking 118 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.87. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Neuropace Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Neuropace Inc

NPCE

7.24 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment